Low birth weight has been linked to an increased risk of pulmonary hypertension (PH) in premature infants needing oxygen therapy for at least 28 days, an analysis revealed. Additionally, the failure, after birth, of the blood vessels of the heart to close — before birth, they’re normally open to…
News
A large proportion of Swedish children younger than 7 who were diagnosed with pulmonary hypertension (PH) started treatment with vasodilators before age 1, and almost all of those treated received Revatio (sildenafil) as a first therapy, according to an analysis of a nationwide prescription registry. Despite treatment, mortality…
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Yutrepia (treprostinil), previously known as LIQ861, as an inhalation treatment for pulmonary arterial hypertension (PAH), its developer Liquidia announced. Tentative approval means that Yutrepia has met all regulatory standards regarding quality, safety, and efficacy required for approval in the U.S. Because…
Local anesthesia is better than general anesthesia for both the mother and her baby when delivery is by cesarean section (C-section) and the woman has pulmonary arterial hypertension (PAH), a study suggests. These findings might help to guide doctors in selecting the best approach to anesthesia for women in labor.
Circulating endostatin, a protein that inhibits new blood vessel formation, appears to correlate well with mortality and disease severity in people with pulmonary arterial hypertension (PAH) in a large, observational study. Blood levels of endostatin show a “clear potential … as a robust prognostic biomarker in PAH” and could…
People with chronic thromboembolic pulmonary hypertension (CTEPH) have significantly worse quality of life at their initial assessment, and higher hospitalization rates over time, relative to idiopathic pulmonary arterial hypertension (IPAH) patients, according to a multicenter study in the U.S. Notably, these quality-of-life differences disappeared over time, and CTEPH…
Potential targets to treat pulmonary arterial hypertension (PAH) were identified by analyzing the gene activity of individual lung endothelial cells isolated from a mouse model of the disease. Study results were validated by cross-referencing them with rat and human gene activity datasets. “The identification of distinct molecular mechanisms and…
Children undergoing high-dose chemotherapy and hematopoietic stem cell transplant (HSCT) to treat their cancer should be screened for pulmonary arterial hypertension (PAH), according to a case report of two young patients at a Pennsylvania hospital. Its authors noted that other reports also suggested “possible links” between such treatments and PAH…
November is Pulmonary Hypertension (PH) Awareness Month, when patients, caregivers, family members, and friends will come together virtually and in person to drive public recognition of the chronic heart and lung disease. The Pulmonary Hypertension Association (PHA), the world’s oldest and largest organization dedicated to PH, is hosting a…
Opsynvi, a fixed-dose oral combination of macitentan and tadalafil, was approved by Health Canada for the long-term treatment of pulmonary arterial hypertension (PAH). It is for use by patients on stable doses of its two active compounds: macitentan (sold as Opsumit) at 10 mg and tadalafil (sold as Adcirca) at 40 mg. Marketed…
By analyzing how medications affect the genetic activity of cells, researchers developed a computational pipeline that may be useful in repurposing cancer treatments for use in other diseases. Leveraging this pipeline, the team identified two compounds, I-BET762 and BRD2889, that might be refined — more quickly and at lower cost…
Global Genes has partnered with the Rare Disease Diversity Coalition (RDDC) to advance health equity for rare disease patients and caregivers in underrepresented communities of color. “For rare disease patients, there are many challenges — and for people of color with a rare disease, these challenges are compounded…
